IASLC WCLC Virtual: KEYNOTE-189 Confirms Continued Benefit of Adding Pembrolizumab to Chemotherapy in Metastatic Non-Small Cell Lung Cancer
No new toxicities have been observed with continued treatment up to 4 years
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.